EGFR and cancer: We investigated the utility of PIP-seq for understanding cancer dynamics by first validating the single-cell transcriptional responses of two cancer cell lines (H1975 and PC9) to gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor.